CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Steven McAllister as Chief Financial Officer, effective immediately. Mr. McAllister has been serving as InVivo’s Interim CFO since December of 2013.
Mr. McAllister previously served as Vice President, Finance and Administration for Biomet Spine and Bone Healing Technologies (a private equity-owned medical device company) from 2007–2013, where he was responsible for all accounting, finance, IT, facilities, and insurance operations activities in addition to leading the company’s strategic planning initiatives. Prior to Biomet, Mr. McAllister spent eight years with Johnson & Johnson’s Medical Device and Diagnostics Group, where he served as Director of Finance for the worldwide spine business, and Director of Finance, Worldwide Operations, for Global Orthopedics. From 1984–1999 he worked in several capacities in Pfizer’s medical device business, which was sold to Stryker in 1998. Mr. McAllister received his BS in Accounting from Fairleigh Dickinson University.
Mark Perrin, InVivo’s Chief Executive Officer, said, “Steve McAllister brings a wealth of experience in financial management. I value the contributions he has made during this transitional period and I am pleased to have him as part of the leadership team.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011 the Company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit, www.invivotherapeutics.com.
